These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23490149)

  • 21. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A.
    Tiberio L; Fletcher L; Eldridge JH; Duncan DD
    Vaccine; 2004 Mar; 22(11-12):1515-23. PubMed ID: 15063577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid IVa incompletely activates MyD88-independent Toll-like receptor 4 signaling in mouse macrophage cell lines.
    Ogura N; Muroi M; Sugiura Y; Tanamoto K
    Pathog Dis; 2013 Apr; 67(3):199-205. PubMed ID: 23620183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity.
    Jiang ZH; Budzynski WA; Qiu D; Yalamati D; Koganty RR
    Carbohydr Res; 2007 May; 342(6):784-96. PubMed ID: 17300769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TLR4 agonists as immunomodulatory agents.
    Alderson MR; McGowan P; Baldridge JR; Probst P
    J Endotoxin Res; 2006; 12(5):313-9. PubMed ID: 17059695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemistry of lipid A: at the heart of innate immunity.
    Molinaro A; Holst O; Di Lorenzo F; Callaghan M; Nurisso A; D'Errico G; Zamyatina A; Peri F; Berisio R; Jerala R; Jiménez-Barbero J; Silipo A; Martín-Santamaría S
    Chemistry; 2015 Jan; 21(2):500-19. PubMed ID: 25353096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acyclic analogues of lipid A: synthesis and biological activities.
    Bulusu MA; Waldstätten P; Hildebrandt J; Schütze E; Schulz G
    J Med Chem; 1992 Sep; 35(19):3463-9. PubMed ID: 1404227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulating the innate immune response by combinatorial engineering of endotoxin.
    Needham BD; Carroll SM; Giles DK; Georgiou G; Whiteley M; Trent MS
    Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1464-9. PubMed ID: 23297218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
    Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
    J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid A receptor TLR4-mediated signaling pathways.
    Yamamoto M; Akira S
    Adv Exp Med Biol; 2010; 667():59-68. PubMed ID: 20665200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human TLR4 polymorphism D299G/T399I alters TLR4/MD-2 conformation and response to a weak ligand monophosphoryl lipid A.
    Yamakawa N; Ohto U; Akashi-Takamura S; Takahashi K; Saitoh S; Tanimura N; Suganami T; Ogawa Y; Shibata T; Shimizu T; Miyake K
    Int Immunol; 2013 Jan; 25(1):45-52. PubMed ID: 22962435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical Synthesis and Immunomodulatory Functions of Bacterial Lipid As.
    Shimoyama A; Fukase K
    Methods Mol Biol; 2023; 2613():33-53. PubMed ID: 36587069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV impairs TNF-alpha release in response to Toll-like receptor 4 stimulation in human macrophages in vitro.
    Tachado SD; Zhang J; Zhu J; Patel N; Koziel H
    Am J Respir Cell Mol Biol; 2005 Dec; 33(6):610-21. PubMed ID: 16109884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parthenolide inhibits LPS-induced inflammatory cytokines through the toll-like receptor 4 signal pathway in THP-1 cells.
    Li S; Gao X; Wu X; Wu Z; Cheng L; Zhu L; Shen D; Tong X
    Acta Biochim Biophys Sin (Shanghai); 2015 May; 47(5):368-75. PubMed ID: 25841439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.
    Anderson RC; Fox CB; Dutill TS; Shaverdian N; Evers TL; Poshusta GR; Chesko J; Coler RN; Friede M; Reed SG; Vedvick TS
    Colloids Surf B Biointerfaces; 2010 Jan; 75(1):123-32. PubMed ID: 19748238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular simplification of lipid A structure: TLR4-modulating cationic and anionic amphiphiles.
    Calabrese V; Cighetti R; Peri F
    Mol Immunol; 2015 Feb; 63(2):153-61. PubMed ID: 24939379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid A structures containing novel lipid moieties: synthesis and adjuvant properties.
    Jiang ZH; Bach MV; Budzynski WA; Krantz MJ; Koganty RR; Longenecker BM
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2193-6. PubMed ID: 12127535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis, and Bioactivity Evaluation of a TF-Based Cancer Vaccine Candidate Using Lipid A Mimetics As a Built-In Adjuvant.
    Gao L; Li G; Qiu C; Ye Y; Li X; Liao P; Ming W; Liu Z; Luo X; Liao G
    J Med Chem; 2024 Jun; 67(12):9976-9990. PubMed ID: 38886162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol.
    Kawasaki K; Akashi S; Shimazu R; Yoshida T; Miyake K; Nishijima M
    J Endotoxin Res; 2001; 7(3):232-6. PubMed ID: 11581576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
    Strobl S; Hofbauer K; Heine H; Zamyatina A
    Chemistry; 2022 Jun; 28(35):e202200547. PubMed ID: 35439332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
    Cluff CW
    Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.